HC Wainwright & Co. Reiterates Buy on BriaCell Therapeutics, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on BriaCell Therapeutics (NASDAQ:BCTX) and maintained a price target of $18.
June 04, 2024 | 10:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on BriaCell Therapeutics and maintained a price target of $18.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100